<DOC>
	<DOC>NCT01966614</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.</brief_summary>
	<brief_title>Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Age ≥50 years Lower Urinary Tract Symptoms (LUTS) attributable to BPH for ≥6 months IPSS ≥15 Maximum urine flow (Qmax) of 5 15 mL/sec Prostate volume of 30 100 mL as determined by TRUS Serum prostatespecific antigen (PSA) values &lt;10 ng/mL Postvoid residual (PVR) &lt;= 200 mL Inability to void ≥125 mL urine Prior surgery/MIST for BPH Presence of or history of certain conditions that could interfere with study results or endanger subject Use of certain prescribed medications that could interfere with study results</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>Lower urinary tract symptoms (LUTS)</keyword>
</DOC>